Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

204
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
204
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

469
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
469
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

170
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
170
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

452
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
452
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

465
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
465
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

1.8K
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
1.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: Patient Perspectives on Artificial Intelligence in Gastroenterology: A Multicenter Survey of Knowledge, Concerns, and Beliefs.

The American journal of gastroenterology·2026
Same author

Fibroblast Growth Factor 21: Mechanisms, Therapeutic Potential, and Clinical Translation in Metabolic Dysfunction.

Drug design, development and therapy·2026
Same author

Patient Perspectives on Artificial Intelligence in Gastroenterology: A Multicenter Survey of Knowledge, Concerns, and Beliefs.

The American journal of gastroenterology·2026
Same author

Incretin-Based Therapies and Post-Bariatric Surgery Alcohol Use Disorder.

JAMA network open·2026
Same author

From Shunt to Strength: Toward an Indian Model of TIPS Prehabilitation.

Journal of clinical and experimental hepatology·2026
Same author

Cost-effectiveness of screening and treatment protocols for treating hepatic encephalopathy in patients diagnosed with dementia.

The American journal of medicine·2026

Related Experiment Video

Updated: Jan 10, 2026

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy
07:10

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy

Published on: June 18, 2020

22.4K

Disease Modulating Agents in Cirrhosis.

Vinay Jahagirdar1, Jasmohan Singh Bajaj2

  • 1Division of Gastroenterology, Hepatology & Nutrition, Department of Internal Medicine, Virginia Commonwealth University, 1200 East Broad Street, 14th Floor, Box 980341, Richmond, VA 23298, USA.

Clinics in Liver Disease
|November 20, 2025
PubMed
Summary
This summary is machine-generated.

This study reviews cirrhosis management, highlighting accurate staging from compensated to decompensated phases. It explores beta-blockers, albumin, and rifaximin as potential disease-modulating therapies for improved patient outcomes.

Keywords:
AlbuminBeta-blockersCirrhosisDecompensationPortal hypertensionRifaximinStatins

More Related Videos

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

5.9K
Invasive Hemodynamic Characterization of the Portal-hypertensive Syndrome in Cirrhotic Rats
09:37

Invasive Hemodynamic Characterization of the Portal-hypertensive Syndrome in Cirrhotic Rats

Published on: August 1, 2018

15.4K

Related Experiment Videos

Last Updated: Jan 10, 2026

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy
07:10

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy

Published on: June 18, 2020

22.4K
A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

5.9K
Invasive Hemodynamic Characterization of the Portal-hypertensive Syndrome in Cirrhotic Rats
09:37

Invasive Hemodynamic Characterization of the Portal-hypertensive Syndrome in Cirrhotic Rats

Published on: August 1, 2018

15.4K

Area of Science:

  • Hepatology and Gastroenterology
  • Pharmacology and Therapeutics

Background:

  • Cirrhosis progression necessitates accurate staging from compensated to decompensated states.
  • Effective management strategies are crucial for altering the disease's natural course.

Purpose of the Study:

  • To evaluate the roles of beta-blockers, albumin, and rifaximin in cirrhosis management.
  • To emphasize their potential as disease-modulating agents.
  • To highlight the need for innovative treatments in altering cirrhosis progression.

Main Methods:

  • Literature review and analysis of current clinical and research frameworks.
  • Evaluation of therapeutic strategies including beta-blockers, albumin, and rifaximin.
  • Focus on disease staging and patient outcome improvement.

Main Results:

  • Beta-blockers, albumin, and rifaximin show potential as disease-modulating agents in cirrhosis.
  • Precise disease staging is critical for effective management.
  • Current therapeutic strategies require further innovation.

Conclusions:

  • Innovative treatments are essential to fundamentally alter the natural course of cirrhosis.
  • Optimizing management through precise staging and targeted therapies like beta-blockers, albumin, and rifaximin can improve patient outcomes.
  • Further research is needed to develop novel therapeutic approaches for cirrhosis.